Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT02354222
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT02354222
-
- Other papers using this trial's data
- Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02354222. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-08-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Teneligliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02354222- Content hash
cb418f599778813ad53d250fd591c6d4a9eb2c150783daddb8f28bbab8fbb1b3